PH12018502278A1 - Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies - Google Patents

Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Info

Publication number
PH12018502278A1
PH12018502278A1 PH12018502278A PH12018502278A PH12018502278A1 PH 12018502278 A1 PH12018502278 A1 PH 12018502278A1 PH 12018502278 A PH12018502278 A PH 12018502278A PH 12018502278 A PH12018502278 A PH 12018502278A PH 12018502278 A1 PH12018502278 A1 PH 12018502278A1
Authority
PH
Philippines
Prior art keywords
dosage regimens
antibodies
dendritic cell
cell antigen
pharmaceutical compositions
Prior art date
Application number
PH12018502278A
Other languages
English (en)
Inventor
Mark R H Krebs
David Dai
Shantanu Sule
Dania Rabah
David Martin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PH12018502278A1 publication Critical patent/PH12018502278A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH12018502278A 2016-04-28 2018-10-26 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies PH12018502278A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
PH12018502278A1 true PH12018502278A1 (en) 2019-09-09

Family

ID=58672794

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502278A PH12018502278A1 (en) 2016-04-28 2018-10-26 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Country Status (14)

Country Link
US (2) US20190284281A1 (https=)
EP (1) EP3448425A1 (https=)
JP (3) JP7045327B2 (https=)
KR (5) KR20240159012A (https=)
CN (2) CN109475623B (https=)
AU (2) AU2017258191B2 (https=)
CA (1) CA3022116A1 (https=)
CO (1) CO2018012506A2 (https=)
EA (1) EA201892443A1 (https=)
IL (2) IL262514B2 (https=)
MA (1) MA44763A (https=)
MX (3) MX2018012945A (https=)
PH (1) PH12018502278A1 (https=)
WO (1) WO2017189827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
AU2021391803A1 (en) * 2020-12-03 2023-07-06 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
JP2026502000A (ja) * 2022-12-28 2026-01-20 デュアリティ・バイオロジクス（シャンハイ）カンパニー・リミテッド 抗ｂｄｃａ２抗体－薬物コンジュゲートおよびその使用
AU2024348487A1 (en) * 2023-09-28 2026-04-23 Nanjing Leads Biolabs Co., Ltd. Bdca2 monoclonal antibody, fusion protein composed of same and taci, and method and use therefor
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
AU2013359419B2 (en) * 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Also Published As

Publication number Publication date
NZ747504A (en) 2025-08-29
JP2024038308A (ja) 2024-03-19
MX2025000037A (es) 2025-02-10
CA3022116A1 (en) 2017-11-02
AU2017258191A1 (en) 2018-11-15
IL262514B1 (en) 2025-08-01
AU2024203240A1 (en) 2024-06-13
KR20220028150A (ko) 2022-03-08
JP2022084782A (ja) 2022-06-07
IL262514A (en) 2018-12-31
WO2017189827A1 (en) 2017-11-02
JP7045327B2 (ja) 2022-03-31
KR20190002563A (ko) 2019-01-08
KR20240159012A (ko) 2024-11-05
AU2017258191B2 (en) 2024-06-13
JP2019520316A (ja) 2019-07-18
BR112018072125A2 (pt) 2019-03-19
KR102366547B1 (ko) 2022-02-23
CN116850282A (zh) 2023-10-10
EA201892443A1 (ru) 2019-04-30
US20190284281A1 (en) 2019-09-19
CN109475623A (zh) 2019-03-15
IL262514B2 (en) 2025-12-01
NZ787392A (en) 2025-08-29
CO2018012506A2 (es) 2018-12-14
MX2018012945A (es) 2019-03-06
IL321561A (en) 2025-08-01
KR20250088784A (ko) 2025-06-17
EP3448425A1 (en) 2019-03-06
US20250289895A1 (en) 2025-09-18
MX2023008075A (es) 2023-07-18
KR20240033168A (ko) 2024-03-12
CN109475623B (zh) 2023-05-26
MA44763A (fr) 2019-03-06

Similar Documents

Publication Publication Date Title
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
PH12020500238A1 (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2016081518A3 (en) Engineered gamma delta t-cells
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX388786B (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP4406969A3 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
PH12015000376B1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
MX2020005373A (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis.
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2020007559A (es) Formulaciones farmaceuticas.
PH12018502139A1 (en) Phosphaplatin liquid formulations